Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY17.33 CNY
Change Today -0.17 / -0.97%
Volume 11.9M
002693 On Other Exchanges
Symbol
Exchange
Shenzhen
As of 3:00 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

hainan shuangcheng pharmac-a (002693) Snapshot

Open
CNY17.46
Previous Close
CNY17.50
Day High
CNY17.76
Day Low
CNY17.09
52 Week High
05/20/15 - CNY17.76
52 Week Low
06/20/14 - CNY6.19
Market Cap
7.0B
Average Volume 10 Days
15.4M
EPS TTM
CNY0.15
Shares Outstanding
405.0M
EX-Date
03/10/15
P/E TM
118.2x
Dividend
CNY0.07
Dividend Yield
0.38%
Current Stock Chart for HAINAN SHUANGCHENG PHARMAC-A (002693)

Related News

No related news articles were found.

hainan shuangcheng pharmac-a (002693) Related Businessweek News

No Related Businessweek News Found

hainan shuangcheng pharmac-a (002693) Details

Hainan Shuangcheng Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of chemically synthesized peptide drugs and active pharmaceutical ingredients. It provides Thymalfasin for injection, which is used in the treatment of chronic hepatitis B, as well as used as a vaccine for patients with immune system functions suppressed; and Levocarnitine for injection to treat carnitine deficiency induced complications. The company also offers Clindamycin Hydrochloride for injection for amygdalitis, suppurative otitis media, and nasosinusitis; acute bronchitis, acute episode of chronic bronchitis, pneumonia, lung abscess, and bronchiectasia concurrent infection; skin and soft tissue infections; urinary system infection, acute urethritis, acute pyelonephritis, and prostatitis; and osteomyelitis, septicemia, peritonitis, and oral infection. In addition, it provides Thymopentin for injection to treat chronic hepatitis B; various primary or secondary T cell immunodeficiency diseases, such as children innate immunodeficiency disease; autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, etc.; various diseases with impaired cell immunity functions; and supplementary treatment of rumor diseases. Further, the company offers Famotidine for injection for patients with peptic ulcer hemorrhage; and intercurrent acute gastric mucosal lesion under stress condition, and gastrointestinal bleeding that is caused by nonsteroidal anti-inflammatory drugs. Additionally, it provides Somatostatin for injection for treating acute haemorrhage from oesophageal varices; acute haemorrhage from gastric or duodenal ulcers, or accompanying acute erosive or haemorrhagic gastritis; pancreas, gallbladder, and intestinal fistula; prophylaxis and postoperative; and diabetic ketoacidosis. The company was founded in 2000 and is based in Haikou, the People’s Republic of China.

Founded in 2000

hainan shuangcheng pharmac-a (002693) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

hainan shuangcheng pharmac-a (002693) Key Developments

Hainan Shuangcheng Pharmaceutical Co., Ltd. Announces Earnings Results for the First Quarter of 2015; Provides Earnings Guidance for the First Half of 2015

Hainan Shuangcheng Pharmaceutical Co., Ltd. announced earnings results for the first quarter of 2015. For the period, the company revealed operating revenue of CNY 27.424 million, rising 17.49% from a year earlier. Net profit attributable to shareholders reached CNY 4.8739 million, declining 20.73%. The company expected net profit of CNY 22.7766 million to CNY 30.8154 million in the first half of 2015, changing from negative 15% to positive 15%.

Hainan Shuangcheng Pharmaceutical Co., Ltd. to Report Q1, 2015 Results on Apr 14, 2015

Hainan Shuangcheng Pharmaceutical Co., Ltd. announced that they will report Q1, 2015 results on Apr 14, 2015

Hainan Shuangcheng Pharmaceutical Co., Ltd., Special/Extraordinary Shareholders Meeting, Mar 31, 2015

Hainan Shuangcheng Pharmaceutical Co., Ltd., Special/Extraordinary Shareholders Meeting, Mar 31, 2015., at 14:30 China Standard Time. Agenda: To consider the restricted stock option incentive plan and its summary; to consider the management measures on implementation and appraisal of restricted stock incentive plan; and to consider the authorization to the board to handle matters in relation to restricted stock incentive plan.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
002693:CH CNY17.33 CNY -0.17

002693 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 002693.
View Industry Companies
 

Industry Analysis

002693

Industry Average

Valuation 002693 Industry Range
Price/Earnings 100.0x
Price/Sales 51.1x
Price/Book 9.7x
Price/Cash Flow 121.8x
TEV/Sales 39.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HAINAN SHUANGCHENG PHARMAC-A, please visit www.shuangchengmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.